Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging showdown: can PSMA PET/CT beat MRI for prostate cancer detection?

NCT ID NCT07533344

Diagnosis Sponsor: Fatih Sultan Mehmet Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 60 men who had a prostate biopsy to check for cancer. It compared two imaging methods used to guide the biopsy: the standard multiparametric MRI and a newer scan called Ga-68 PSMA PET/CT. The goal was to see which method better finds aggressive prostate cancers. The results could help doctors choose the best imaging tool for biopsy guidance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ga-68 PSMA (a radioactive tracer used in PET/CT imaging)
What this could lead to
If PSMA PET/CT proves better than MRI at guiding biopsies, it could become a new standard for detecting aggressive prostate cancers more accurately.
What could go wrong
This is a small, retrospective study (60 patients) that only compares imaging methods, not a treatment trial. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Aug 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged ≥40 years who underwent cognitive prostate biopsy for suspected prostate cancer with pre-biopsy imaging using multiparametric prostate MRI or Ga-68 PSMA PET/CT between 2020 and 2024.

Ages

40 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients aged 40 years or older * Patients who underwent cognitive prostate biopsy between 2020 and 2024 * Patients who had pre-biopsy imaging with multiparametric prostate MRI or Ga-68 PSMA PET/CT * Patients with available prostate biopsy pathology results * Patients with prostate lesions scored PIRADS 4 or 5 on multiparametric prostate MRI Exclusion Criteria: * Patients with incomplete clinical or imaging data * Patients without available histopathological biopsy results * Patients who underwent prostate biopsy without pre-biopsy imaging * Patients with lesions scored PIRADS ≤3 on multiparametric prostate MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Fatih Sultan Mehmet Training and Research Hospital

    Istanbul, Istanbul, 34752, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.